Secondary CMV disease may occur in CMV- seropositive (R+) SOT recipients, either as reactivation (of endogenous latent CMV in the recipient) or super- infection (with CMV transmitted by transplantation) ( 23). Allostimulation, allograft rejection, and intense pharmacologic immunosuppression, particularly with antithymocyte-immunoglobulin therapy, combine to provide an environment that permits CMV reactivation after SOT ( 25)
If you want to change selection, open document below and click on "Move attachment"
- (no access) - CMV ASM.pdf, p3
|status||not read|| ||reprioritisations|
|last reprioritisation on|| ||suggested re-reading day|
|started reading on|| ||finished reading on|